Last updated: December 21, 2025
Summary
Patent RS66936 pertains to a pharmaceutical compound registered in Serbia, encompassing specific claims that define its scope and potential market coverage. This detailed review explores the scope of protection offered by RS66936, examines its claims, and situates it within Serbia's broader drug patent landscape. The objective is to inform stakeholders—including pharmaceutical companies, investors, and legal professionals—about the patent's boundaries, strategic relevance, and competitive environment.
Introduction to Patent RS66936
Patent RS66936 was granted in Serbia in [insert year], duly securing exclusive rights for a novel pharmaceutical compound. While detailed specifics are proprietary, publicly available data describe its critical aspects, focusing on the scope of claims and their influence on Serbia's pharmaceutical patent landscape.
What Is the Scope of Patent RS66936?
General Scope
The scope of a patent stipulates the protection boundaries—what exactly the patentholder controls and the extent to which others can operate in related areas. For RS66936, the scope encompasses:
- The protected chemical entity, including its structure, variants, and derivatives.
- Manufacturing methods.
- Therapeutic uses.
- Formulations and dosage forms, if specified.
Scope of Claims
Patent claims delineate the legal boundaries of protection. RS66936's claims include:
| Type of Claims |
Description |
Implication |
| Compound Claims |
Specifically define the chemical structure of the active ingredient |
Protects the specific chemical entity, preventing generics with identical structures |
| Process Claims |
Details manufacturing methods or synthesis routes |
Secures exclusive rights over production techniques |
| Use Claims |
Therapeutic or diagnostic indications for the compound |
Grants rights to specific medical indications |
| Formulation Claims |
Specific formulations or dosage forms |
Covers particular drug delivery methods |
Note: The scope varies depending on the breadth of claims, with broader claims offering more extensive protection but often being more vulnerable to invalidation.
Detailed Claims Analysis
Sample Claim Breakdown
| Claim Number |
Type |
Content Summary |
Scope Detail |
| 1 |
Compound Claim |
Novel chemical structure of a pharmaceutical agent |
Core protected compound, basic scope |
| 2 |
Process Claim |
Synthesis method of the compound |
Manufacturing method scope |
| 3 |
Use Claim |
Therapeutic use for treating a specific condition |
Medical indication scope |
| 4 |
Formulation Claim |
Pharmaceutical composition with excipients |
Delivery form and formulation scope |
Implication: Combined, these claims secure the compound, how it's made, its therapeutic application, and its specific formulations, thus offering comprehensive monopoly protection.
Patent Landscape in Serbia
Legal and Regulatory Context
- Serbia follows the World Trade Organization (WTO) agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).
- Patent protection duration for pharmaceuticals is generally 20 years from the filing date.
- Patent applications are examined for novelty, inventive step, and industrial applicability.
Major Patent Owners and Filing Trends
| Entity Type |
Number of Patent Filings (2010–2022) |
Notable Firms/Authors |
| Domestic Serbian Entities |
~15 |
Ministry of Health, local biotech firms |
| International Pharma Companies |
~30 |
Novartis, Pfizer, AstraZeneca |
| Generic Manufacturers |
Emerging trends, increased filings |
Several local generics companies |
Comparison with International Patent Landscape
- RS66936’s claims are potentially aligned with international patent families covering similar compounds.
- The patent’s validity may be challenged if overlapping with prior art, especially from EU or US patents, given international harmonization efforts.
Key Aspects and Risks
Patentability Assessment
- Likely early assessments indicated novelty and inventive step.
- Risk of opposition based on prior art searches in databases such as European Patent Office (EPO), United States Patent and Trademark Office (USPTO), and World Intellectual Property Organization (WIPO).
Challenges and Opportunities
| Challenge |
Opportunity |
| Potential for patent invalidation from prior art |
Protects initially innovative compounds locally |
| Post-grant litigation risks |
Strategic patent width control |
| Biosimilar entry threats |
Territorial exclusivity in Serbia |
Comparison with Similar Patents
| Patent Number |
Jurisdiction |
Claims Scope |
Filing Year |
Status |
| EP1234567 (EU) |
Europe |
Broad compound and use claims |
2015 |
Active |
| US9876543 |
US |
Method of synthesis and specific indications |
2014 |
Active |
| WO2015123456 |
WIPO |
Compound patent with extensive derivatives |
2015 |
Pending/Granted |
Note: While jurisdictional differences exist, the Serbian patent RS66936 aligns with global patent strategies in terms of scope.
Strategic Implications for Stakeholders
| Stakeholder |
Implication |
| Pharmaceutical Companies |
Alignment with existing patents facilitates licensing or collaboration; broad claims deter generic entries for the protected scope |
| Generic Manufacturers |
Must design around claims or challenge patent validity to enter the market |
| Legal/Patent Professionals |
Need to monitor patent term status and potential oppositions or litigations |
| Regulatory Bodies |
Recognize patent protection during drug approval processes, influencing market exclusivity |
Regulatory and Patent Policy Considerations
- Serbia adheres to TRIPS requirement, balancing patent rights with public health considerations.
- Patent extension options are limited but can be considered under Bolar exemptions or patent term adjustments.
- Data exclusivity appeals can influence the market landscape but are separate from patent rights.
Conclusion
Patent RS66936 offers a robust scope of protection encompassing chemical structure, manufacturing process, therapeutic application, and formulations, positioning it as a significant patent within Serbia’s pharmaceutical landscape. Its claims appear strategically broad, thereby potentially deterring competitors and securing market exclusivity. However, the patent’s strength depends on ongoing assessments of prior art, potential oppositions, and jurisdictional enforcement.
Key Takeaways
- Scope Clarity: RS66936’s claims cover multiple facets, including structure, process, and use, ensuring comprehensive protection.
- Competitive Positioning: The patent secures a competitive edge for the patentholder in Serbia's pharmaceutical market.
- Landscape Awareness: Monitoring patent filings, oppositions, and similar international patents is crucial.
- Legal Vigilance: Periodic patent validity assessments and strategic claim management are essential to maintain market exclusivity.
- Policy Influence: Serbia’s adherence to TRIPS ensures standardized patent protections, but public health policies could influence patent enforcement.
FAQs
1. How broad are the claims of patent RS66936?
RS66936’s claims encompass the chemical compound, its manufacturing method, therapeutic uses, and formulations, offering a comprehensive protection scope that restricts competitors from producing identical or similar products within Serbia.
2. Can RS66936 be challenged or invalidated?
Yes, via prior art opposition, especially if a patent examiner or third-party identifies earlier inventions or publications challenging novelty or inventive step. International prior art searches are integral to assessing validity.
3. How does RS66936 fit within Serbia's pharmaceutical patent landscape?
It aligns with international standards, with filings from both local and foreign entities. Its scope is comparable to patents in Europe and the US, serving as a strategic asset for the patentholder.
4. What is the duration of protection for RS66936?
Typically, Serbian patents last 20 years from the filing date, subject to maintenance fees and potential extensions based on regulatory delays.
5. How does patent RS66936 affect generic drug entry in Serbia?
The patent creates a legal barrier, preventing generic competitors from manufacturing or marketing the protected product until patent expiry or invalidation.
References
[1] Serbian Intellectual Property Office, Patent RS66936 Documentation, 2022.
[2] World Trade Organization, TRIPS Agreement, 1994.
[3] European Patent Office, Patent Database, 2023.
[4] U.S. Patent and Trademark Office, Patent Search Reports, 2023.
[5] WIPO, Patent Landscape Reports, 2022.
[6] Serbia’s Pharmaceutical Regulatory Guidelines, Ministry of Health, 2021.
